Luks, Andrew M., Thomas G. DeLoughery, Jeffrey H. Gertsch, and Suzy Stokes. Clinical conundrum: return to high altitude after cerebral venous sinus thrombosis. High Alt Med Biol. 25:337–341, 2024.
Get full access to this article
View all access options for this article.
References
1.
Aguiar de SousaD, Lucas NetoL, CanhaoP, et al.Recanalization in cerebral venous thrombosis. Stroke, 2018; 49(8):1828–1835.
2.
BasnyatB, WuT, GertschJH. Neurological conditions at altitude that fall outside the usual definition of altitude sickness. High Alt Med Biol, 2004; 5(2):171–179.
3.
BergerMM, LuksAM. High altitude. Semin Respir Crit Care Med, 2023; 44(5):681–695.
GeisbuschC, HerwehC, GumbingerC, et al.Chronic intracranial hypertension after cerebral venous and sinus thrombosis - frequency and risk factors. Neurol Res Pract, 2021; 3(1):28.
6.
GrangerCB, AlexanderJH, McMurrayJJ, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365(11):981–992.
7.
GuptaN, AshrafMZ. Exposure to high altitude: A risk factor for venous thromboembolism? Semin Thromb Hemost, 2012; 38(2):156–163.
8.
HassanWU, SyedMJ, AlamgirW, et al.Cerebral venous thrombosis at high altitude: Analysis of 28 cases. Cerebrovasc Dis, 2019; 48(3-6):184–192.
9.
KhanF, RahmanA, CarrierM, et al.Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: Systematic review and meta-analysis. BMJ, 2019; 366:l4363.
10.
KhattarNK, SumardiF, ZemmarA, et al.Cerebral venous thrombosis at high altitude: A retrospective cohort of twenty-one consecutive patients. Cureus, 2019; 11(6):e4940.
11.
LaneDA, WoodK. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation, 2015; 131(16):e412–e415.
12.
LuksAM, BeidlemanBA, FreerL, et al.Wilderness medical society clinical practice guidelines for the prevention, diagnosis, and treatment of acute altitude illness: 2024 update. Wilderness Environ Med, 2024; 35(1_suppl):2S–19S.
13.
LuoS, Au YeungSL, ZhaoJV, et al.Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: Mendelian randomisation study in UK Biobank. BMJ, 2019; 364:l476.
14.
MartinDS, PateJS, VercueilA, et al.Reduced coagulation at high altitude identified by thromboelastography. Thromb Haemost, 2012; 107(6):1066–1071.
15.
MartinelliI, SacchiE, LandiG, et al.High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med, 1998; 338(25):1793–1797.
16.
MartinezC, SuissaS, RietbrockS, et al.Testosterone treatment and risk of venous thromboembolism: Population based case-control study. BMJ, 2016; 355:i5968.
17.
McKerrow JohnsonI, ShatzelJ, OlsonS, et al.Travel-associated venous thromboembolism. Wilderness Environ Med, 2022; 33(2):169–178.
SaposnikG, BushnellC, CoutinhoJM, et al.Diagnosis and management of cerebral venous thrombosis: A scientific statement from the American Heart Association. Stroke, 2024; 55(3):e77–e90.
20.
SwensonER, MaggioriniM, MongovinS, et al.Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. JAMA, 2002; 287(17):2228–2235.
